The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review
Abstract
IMPORTANCE: In the past decade, ERBB2 (formerly HER2)-directed antibody-drug conjugates (ADCs) have substantially changed treatment of both advanced and early-stage ERBB2-positive breast cancer. Novel conjugates are now showing activity in trials of other ERBB2-associated tumors, leading to the recent US Food and Drug Administration approval of trastuzumab deruxtecan for ERBB2-positive gastric cancer, as well as beneficial results in colorectal, lung, and bladder cancer. It is thus possible that anti-ERBB2 ADCs may become a treatment option for multiple types of tumors because many have at least some expression of ERBB2. Despite an improved overall therapeutic index, clinical observations have recently raised a concern regarding potential lung toxicity of anti-ERBB2 ADCs. Deaths related to interstitial lung disease (ILD) have been reported with variable incidence in trials testing anti-ERBB2 conjugates, warranting appropriate training of clinicians for the identification and management of this toxic effect. OBSERVATIONS: Although no specific guidelines are available for the diagnosis and management of ADC-related ILD, some recommendations can be derived based on general principles adopted for drug-induced and immunotherapy-related ILD. Overall, in symptomatic ILD, the ADC should be discontinued. Reintroduction of the conjugate can be considered only in asymptomatic cases after complete resolution. Corticosteroids represent the cornerstone of ILD treatment, and dosing should be adapted according to the severity of the event. Additional treatments can be considered based on the clinical scenario. CONCLUSIONS AND RELEVANCE: This review summarizes the current knowledge on the pathogenesis and epidemiologic characteristics of anti-ERBB2 ADC-related lung toxicity, proposing strategies for its diagnosis and treatment. Earlier diagnosis and more adequate treatment of ADC-induced ILD may improve the therapeutic index of this important class of anticancer agents, allowing for a safe expansion of anti-ERBB2 ADCs across tumor types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Time course of bleomycin‐induced lung fibrosis
Izbicki, G., Segel, M. J., Christensen, T. G., Conner, M. W., & Breuer, R. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00220.x · Cited by 447
Siena, S., Di Bartolomeo, M., Raghav, K. P. S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4000 · Cited by 54
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H. J., Carey, L. A., Cortes, J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.008 · Cited by 312
Self-citationLustberg, M. B., Kuderer, N. M., Desai, A., Bergerot, C., & Lyman, G. H. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00776-9 · Cited by 306
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269
Self-citation
Metadata
- Authors
- Tarantino, P., Modi, S., Tolaney, S. M., Cortés, J., Hamilton, E. P., Kim, S.-B., Toi, M., Andrè, F., & Curigliano, G.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-12-01
- Volume
- 7
- Issue
- 12
- Pages
- 1873
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3205051299
- Cited by
- 172
- References
- 6
- FWCI
- 13.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. https://app.cochat.ai/papers/10.1001/jamaoncol.2021.3595
- The paper
- Tarantino, P., Modi, S., Tolaney, S. M., Cortés, J., Hamilton, E. P., Kim, S.-B., Toi, M., Andrè, F., & Curigliano, G. (2021). Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2021.3595
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.